- Home
- NKTR
NKTR
Nektar Therapeutics
as 01-21-2025 4:00pm EST
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 247.9M | IPO Year: | 1994 |
| Target Price: | $4.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $1.93 | Next Earning Date: | 03-03-2025 |
| Revenue: | $93,137,000 | Revenue Growth: | 5.53% |
| Revenue Growth (this year): | 12.85% | Revenue Growth (next year): | -11.40% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Dec 23 '24 | Sell | $0.90 | 49,962 | $44,800.20 | 351,892 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Dec 19 '24 | Sell | $0.94 | 51,115 | $48,048.10 | 326,904 | |
| ROBIN HOWARD W | NKTR | President & CEO | Dec 17 '24 | Sell | $1.00 | 132,030 | $131,649.60 | 1,110,675 | |
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Nov 19 '24 | Sell | $1.01 | 6,407 | $6,471.07 | 351,892 | |
| ROBIN HOWARD W | NKTR | President & CEO | Nov 19 '24 | Sell | $1.01 | 16,278 | $16,440.78 | 1,110,675 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Nov 19 '24 | Sell | $1.01 | 7,785 | $7,862.85 | 326,904 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
PR Newswire
12 days ago
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
MT Newswires
14 days ago
B. Riley Starts Nektar Therapeutics With Buy Rating, $4 Price Target
Insider Monkey
15 days ago
Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media?
Simply Wall St.
18 days ago
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership
MT Newswires
a month ago
HC Wainwright Initiates Nektar Therapeutics at Buy With $6.50 Price Target
PR Newswire
a month ago
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
PR Newswire
2 months ago
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Simply Wall St.
2 months ago
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.